Review article · 2014 · Open access
Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options
Neuropsychiatric Disease and Treatment, 10, 777 · Published 1 May 2014 · DOI 10.2147/ndt.s43404
In brief
“Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options” is a 2014 review article by Pierre S. Chue and Justine K. Lalonde, published in Neuropsychiatric Disease and Treatment. OpenAlex counts 87 citations as of 20 November 2026. It is open access under a CC BY-NC licence: the full text is free to read at Neuropsychiatric Disease and Treatment.
- Citations
- 87
- Most cited in
- 2016 (12)
- Field-weighted impact
- 1.59
- References
- 121
- Authors
- 2
Abstract
The negative symptoms of schizophrenia represent an impairment of normal emotional responses, thought processes and behaviors, and include blunting or flattening of affect, alogia/aprosody, avolition/apathy, anhedonia, and asociality. Negative symptoms contribute to a reduced quality of life, increased functional disability, increased burden of illness, and poorer long-term outcomes, to a greater degree than positive symptoms. Primary negative symptoms are prominent and persistent in up to 26% of patients with schizophrenia, and they are estimated to occur in up to 58% of outpatients at any given time. Negative symptoms respond less well to medications than positive symptoms, and to date treatment options for negative symptoms have been limited, with no accepted standard treatment. Modest benefits have been reported with a variety of different agents, including second-generation antipsychotics and add-on therapy with antidepressants and other pharmacological classes. Recent clinical research focusing on negative symptoms target novel biological systems, such as glutamatergic neurotransmission. Different approaches include: enhancing N-methyl-D-aspartate receptor function with agents that bind directly to the glycine ligand site or with glycine reuptake inhibitors; influencing the metabotropic glutamate receptor (mGluR2/3) with positive allosteric modulators; and stimulating nicotinic acetylcholine receptors. In conclusion, the lack of clearly efficacious pharmacological treatments for the management of negative symptoms represents a significant unmet need, especially considering the importance of these symptoms on patient outcomes. Hence, further research to identify and characterize novel pharmacological treatments for negative symptoms is greatly needed.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Chue, P. S., & Lalonde, J. K. (2014). Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options. Neuropsychiatric Disease and Treatment, 10, 777. https://doi.org/10.2147/ndt.s43404
MLA 9
Chue, Pierre S., and Justine K. Lalonde. “Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options.” Neuropsychiatric Disease and Treatment, vol. 10, 2014, p. 777. https://doi.org/10.2147/ndt.s43404.
Chicago
Chue, Pierre S. and Justine K. Lalonde. 2014. “Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options.” Neuropsychiatric Disease and Treatment 10: 777. https://doi.org/10.2147/ndt.s43404.
Harvard
Chue, P. S. and Lalonde, J. K. (2014) ‘Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options’, Neuropsychiatric Disease and Treatment, 10, p. 777. doi:10.2147/ndt.s43404.
IEEE
P. S. Chue and J. K. Lalonde, “Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options,” Neuropsychiatric Disease and Treatment, vol. 10, p. 777, 2014, doi: 10.2147/ndt.s43404.
BibTeX
@article{chue2014addressing,
title = {{Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options}},
author = {Chue, Pierre S. and Lalonde, Justine K.},
journal = {Neuropsychiatric Disease and Treatment},
year = {2014},
volume = {10},
pages = {777},
doi = {10.2147/ndt.s43404},
url = {https://doi.org/10.2147/ndt.s43404}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2016 | 12 | |
| 2017 | 12 | |
| 2018 | 10 | |
| 2019 | 7 | |
| 2020 | 7 | |
| 2021 | 9 | |
| 2022 | 3 | |
| 2023 | 1 | |
| 2025 | 1 | |
| 2026 | 2 |
Its field-weighted citation impact is 1.59: it has been cited 1.59 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- schizophrenia
- negative symptoms
- unmet medical needs
- pharmacotherapy
- NMDA receptor agonist
- mGluR2/3
- positive allosteric modulators
- nicotinic acetylcholine receptors
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Chue, P. S., & Lalonde, J. K. (2014). Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options. Neuropsychiatric Disease and Treatment, 10, 777. https://doi.org/10.2147/ndt.s43404
How many times has this paper been cited?
87 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Neuropsychiatric Disease and Treatment: sign in and open the PDF from this page.
Who wrote this paper?
Pierre S. Chue, Justine K. Lalonde.
What is the DOI of this paper?
10.2147/ndt.s43404, permanently at https://doi.org/10.2147/ndt.s43404. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.